FMP
NuGenerex Immuno-Oncology, Inc.
NUGX
OTC
Inactive Equity
NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer. The company was formerly known as Antigen Express, Inc. The company was founded in 1993 and is based in Miramar, Florida. NuGenerex Immuno-Oncology, Inc.is a subsidiary of Generex Biotechnology Corporation.
0.0001 USD
0 (0%)
Earnings
We are unable to load the chart at this time.
Dividends
We are unable to load the chart at this time.
Splits
We are unable to load the chart at this time.
From:
To:
Date
Revenue
Earnings
Estimated Earnings
Surprise
No data found!
